Home/Filings/4/0001562180-16-001511
4//SEC Filing

TriVascular Technologies, Inc. 4

Accession 0001562180-16-001511

CIK 0001432732operating

Filed

Feb 3, 7:00 PM ET

Accepted

Feb 4, 4:36 PM ET

Size

19.9 KB

Accession

0001562180-16-001511

Insider Transaction Report

Form 4
Period: 2016-02-03
CHAVEZ CHRISTOPHER G
DirectorPresident, CEO and Chairman
Transactions
  • Exercise/Conversion

    Common Stock

    2016-02-03+83,603743,555 total
  • Disposition to Issuer

    Common Stock

    2016-02-0360,168659,952 total
  • Tax Payment

    Common Stock

    2016-02-03$5.62/sh23,435$131,705720,120 total
  • Exercise/Conversion

    Common Stock

    2016-02-03$3.25/sh+29,720$96,590689,672 total
  • Disposition to Issuer

    Common Stock

    2016-02-038,441659,952 total
  • Exercise/Conversion

    Stock Options (Right to buy)

    2016-02-0329,7200 total
    Exercise: $3.25Exp: 2023-02-20Common Stock (29,720 underlying)
  • Tax Payment

    Common Stock

    2016-02-03$5.62/sh21,279$119,588668,393 total
  • Disposition to Issuer

    Common Stock

    2016-02-03659,9520 total
  • Exercise/Conversion

    Restricted Stock Units (RSU)

    2016-02-0383,6030 total
    Common Stock (83,603 underlying)
Footnotes (7)
  • [F1]Each RSU represents a contingent right to receive one share of TRIV common stock.
  • [F2]This quantity includes 5,906 ESPP shares.
  • [F3]These shares were withheld by the issuer to satisfy tax withholding obligations and calculated for the purposes of the deemed settlement of the RSUs, contingent upon the closing of the Merger (as defined below), utilizing the closing price of the issuers common stock on January 28, 2016.
  • [F4]These shares were disposed of pursuant to the merger agreement between the issuer and Endologix, Inc. (such transaction, the Merger). In connection with the closing of the Merger, the reporting person received 0.6312 share of Endologix common stock and $0.34 in cash for each share of issuer common stock held by such reporting person, for a total consideration of $4.95 per share based upon the closing price of Endologix common stock on February 2, 2016.
  • [F5]These shares were withheld by the issuer as payment of the exercise price and to satisfy tax withholding obligations, and calculated for the purposes of the deemed exercise of the options, contingent upon the closing of the Merger, utilizing the closing price of the issuers common stock on January 28, 2016.
  • [F6]These restricted stock units became 100% vested in connection with the Merger.
  • [F7]These stock options became 100% vested in connection with the Merger.

Issuer

TriVascular Technologies, Inc.

CIK 0001432732

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001432732

Filing Metadata

Form type
4
Filed
Feb 3, 7:00 PM ET
Accepted
Feb 4, 4:36 PM ET
Size
19.9 KB